Wednesday, 18 June 2014

Selexipag Meets Primary Endpoint in Pivitol Phase III Griphon Outcome Study in Patients with Pulmonary Arterial Hypertension « New Drug Approvals

Selexipag Meets Primary Endpoint in Pivitol Phase III Griphon Outcome Study in Patients with Pulmonary Arterial Hypertension « New Drug Approvals:



'via Blog this'
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)